Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 15/20 | 1.00 |
| ▸ | DRD2 | P14416 | 15/20 | 1.00 |
| ▸ | DRD3 | P35462 | 12/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | THPO | P40225 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 0.89 |
| ▸ | LMNA | P02545 | 1/20 | 0.89 |
| ▸ | THRB | P10828 | 1/20 | 0.89 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.89 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pd-168,077 SCHEMBL29435417 | 1.00 | DRD4 (1.00) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| Pd-168,077 SCHEMBL30730667 | 0.94 | KDM4E (1.00) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL14908000 | 0.88 | DRD4 (0.78) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL4010683 | 0.88 | DRD4 (1.00) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL4001572 | 0.87 | DRD2 (1.00) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL4002664 | 0.87 | DRD2 (1.00) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL4011209 | 0.85 | DRD4 (0.73) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL12648568 | 0.84 | DRD2 (0.78) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL4002926 | 0.83 | DRD2 (1.00) | DRD4DRD2DRD3KDM4EALDH1A1 | |
| SCHEMBL4006407 | 0.82 | DRD2 (0.69) | DRD4DRD2DRD3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4378532-B1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2025-11-12 | — | — | EP | claimed |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2025-06-05 | — | — | US | claimed |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2024-08-01 | — | — | US | claimed |
| EP-3745862-B1 | D1 DOPAMINE RECEPTOR AGONISTS FOR TREATING FIBROTIC PATHOLOGIES | MAYO FOUND MEDICAL EDUCATION & RES (US) | 2024-06-26 | — | — | EP | claimed |
| EP-4378532-A2 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2024-06-05 | — | — | EP | claimed |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2023-11-02 | — | — | US | claimed |
| EP-4003348-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | Mayo Foundation for Medical Education and Research (US) | 2022-06-01 | — | — | EP | claimed |
| US-20180064707-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING POSTTRAUMATIC STRESS DISORDER | POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) | 2018-03-08 | — | — | US | claimed |
| US-20140256738-A1 | USE OF SELECTIVE DOPAMINE D4 RECEPTOR AGONISTS FOR TREATING SEXUAL DYSFUNCTION | ABBVIE INC. | 2014-09-11 | — | — | US | claimed |
| EP-1345608-B1 | SELECTIVE DOPAMINE D4 RECEPTOR AGONISTS FOR TREATING SEXUAL DYSFUNCTION | ABBOTT LAB (US) | 2007-04-04 | — | — | EP | claimed |
| US-20060276484-A1 | Use of selective dopamine D4 receptor agonists for treating sexual dysfunction | ABBVIE INC. | 2006-12-07 | — | — | US | claimed |
| EP-1509213-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2005-03-02 | — | — | EP | claimed |
| CN-1531434-A | Selective dopamine D for treating sexual dysfunction4Receptor agonists | ���Ͽع�����˾ | 2004-09-22 | — | — | CN | claimed |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2004-02-12 | — | — | US | claimed |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-18 | — | — | US | claimed |
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | ABBOTT LABORATORIES | 2003-12-11 | — | — | US | claimed |
| WO-2003099266-A2 | ACETAMIDES AND BENZAMIDES THAT ARE USEFUL IN TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2003-12-04 | — | — | WO | claimed |
| EP-1345608-A2 | THE USE OF SELECTIVE DOPAMINE D4 RECEPTOR AGONISTS FOR TREATING SEXUAL DYSFUNCTION | Abbott Laboratories (US) | 2003-09-24 | — | — | EP | claimed |
| US-20020103105-A1 | Treatment of male erectile dysfunction | ABBOTT LABORATORIES | 2002-08-01 | — | — | US | claimed |
| WO-2002041894-A2 | SELECTIVE DOPAMINE D4 RECEPTOR AGONISTS FOR TREATING SEXUAL DYSFUNCTION | ABBOTT LABORATORIES (US) | 2002-05-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229094-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | DRD4 1497/4885DRD2 1644/4885DRD3 1700/4885 |
| US-20250179086-A1 | COMPOUNDS AND METHODS FOR TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD4 4877/4885DRD2 4882/4885DRD3 4873/4885 |
| US-20040029887-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | DRD4 1497/4885DRD2 1644/4885DRD3 1700/4885 |
| US-20240252463-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD4 4861/4885DRD2 4879/4885DRD3 4860/4885 |
| US-20030232836-A1 | Acetamides and benzamides that are useful in treating sexual dysfunction | CATSPER1, CYP19A1, PDE12 | DRD4 1497/4885DRD2 1644/4885DRD3 1700/4885 |
| US-20230346740-A1 | METHODS OF TREATING FIBROTIC PATHOLOGIES | MMP1, MMP8, COL2A1 | DRD4 4861/4885DRD2 4879/4885DRD3 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.